ES2605495T3 - Solución de atomoxetina - Google Patents
Solución de atomoxetina Download PDFInfo
- Publication number
- ES2605495T3 ES2605495T3 ES13818182.1T ES13818182T ES2605495T3 ES 2605495 T3 ES2605495 T3 ES 2605495T3 ES 13818182 T ES13818182 T ES 13818182T ES 2605495 T3 ES2605495 T3 ES 2605495T3
- Authority
- ES
- Spain
- Prior art keywords
- solution
- atomoxetine
- range
- flavor
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960002430 atomoxetine Drugs 0.000 title abstract description 10
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 title abstract 3
- 239000000243 solution Substances 0.000 abstract description 22
- 239000000796 flavoring agent Substances 0.000 abstract description 10
- 240000007651 Rubus glaucus Species 0.000 abstract description 6
- 235000011034 Rubus glaucus Nutrition 0.000 abstract description 6
- 235000009122 Rubus idaeus Nutrition 0.000 abstract description 6
- 235000019634 flavors Nutrition 0.000 abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- 239000007864 aqueous solution Substances 0.000 abstract description 4
- 235000013355 food flavoring agent Nutrition 0.000 abstract description 4
- 235000003599 food sweetener Nutrition 0.000 abstract description 4
- 239000003765 sweetening agent Substances 0.000 abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- LUCXVPAZUDVVBT-UNTBIKODSA-N atomoxetine hydrochloride Chemical compound Cl.O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C LUCXVPAZUDVVBT-UNTBIKODSA-N 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 229960002828 atomoxetine hydrochloride Drugs 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361901577P | 2013-11-08 | 2013-11-08 | |
| US201361901577P | 2013-11-08 | ||
| PCT/US2013/076435 WO2014204513A1 (en) | 2013-11-08 | 2013-12-19 | Atomoxetine solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2605495T3 true ES2605495T3 (es) | 2017-03-14 |
Family
ID=49920679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13818182.1T Active ES2605495T3 (es) | 2013-11-08 | 2013-12-19 | Solución de atomoxetina |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9326935B2 (https=) |
| EP (1) | EP2838510B1 (https=) |
| JP (1) | JP5973073B2 (https=) |
| CN (1) | CN105705135A (https=) |
| CY (1) | CY1118100T1 (https=) |
| DK (1) | DK2838510T3 (https=) |
| ES (1) | ES2605495T3 (https=) |
| HU (1) | HUE032205T2 (https=) |
| IL (1) | IL244878A (https=) |
| MX (1) | MX365663B (https=) |
| PL (1) | PL2838510T3 (https=) |
| PT (1) | PT2838510T (https=) |
| SI (1) | SI2838510T1 (https=) |
| TW (1) | TWI583402B (https=) |
| WO (1) | WO2014204513A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105726473A (zh) * | 2016-03-31 | 2016-07-06 | 北京万全德众医药生物技术有限公司 | 托莫西汀或其可药用盐口服溶液及其制备方法 |
| CN106727291B (zh) * | 2016-12-06 | 2020-02-11 | 山东达因海洋生物制药股份有限公司 | 一种盐酸托莫西汀口服溶液及其制备方法 |
| US9855228B1 (en) * | 2016-12-14 | 2018-01-02 | Taho Pharmaceuticals Ltd. | Oral solution comprising atomoxetine hydrochloride and methods thereof |
| CN111437247A (zh) * | 2019-01-17 | 2020-07-24 | 北京万全德众医药生物技术有限公司 | 一种托莫西汀口服液的制备方法 |
| CN112438949A (zh) * | 2019-09-05 | 2021-03-05 | 北京兴源联合医药科技有限公司 | 一种含钙补充剂的盐酸托莫西汀口服液及其制备方法 |
| CN112451476A (zh) * | 2019-09-09 | 2021-03-09 | 北京兴源联合医药科技有限公司 | 一种盐酸托莫西汀口服液及其制备方法 |
| CN111956607A (zh) * | 2020-09-25 | 2020-11-20 | 健民药业集团股份有限公司 | 盐酸托莫西汀口服溶液及其制备方法 |
| CN115869253A (zh) * | 2021-09-28 | 2023-03-31 | 郑州深蓝海生物医药科技有限公司 | 一种盐酸托莫西汀口服溶液及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR75395B (https=) | 1980-11-14 | 1984-07-13 | Lilly Co Eli | |
| US5658590A (en) | 1995-01-11 | 1997-08-19 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| AU4529101A (en) * | 2000-03-07 | 2001-09-17 | Eli Lilly And Company | Treatment of psoriasis |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
| AU2004312059A1 (en) | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Atomoxetine formulations |
| CN101155775A (zh) * | 2005-04-05 | 2008-04-02 | 特瓦药物精化学品股份有限公司 | 稳定的阿托莫西汀盐酸盐、其制备方法，以及其稳定性分析控制 |
| JP2008501721A (ja) | 2005-04-05 | 2008-01-24 | テバ ファーマシューティカル ファイン ケミカルズ ソチエタ レスポンサビリタ リミテ | 安定性アトモキセチン塩酸塩、その調製方法及びその安定性の分析的調節 |
| US20070134277A1 (en) * | 2005-12-09 | 2007-06-14 | Children's Medical Center Corporation | Pharmaceutical formulation for sulfur-containing drugs in liquid dosage forms |
| WO2007103687A2 (en) | 2006-03-01 | 2007-09-13 | Tristrata, Inc. | Composition and method for topical treatment of tar-responsive dermatological disorders |
| US20080031932A1 (en) | 2006-08-04 | 2008-02-07 | Watson Laboratories, Inc. | Transdermal atomoxetine formulations and associated methods |
| US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| US20080145318A1 (en) | 2006-12-13 | 2008-06-19 | Midha Kamal K | Atomoxetine formulations and associated methods |
| EP2512460A4 (en) | 2009-12-18 | 2015-01-21 | Exodos Life Sciences Ltd Partnership | METHOD AND COMPOSITIONS FOR STABLE LIQUID ACTIVE FORMULATIONS |
| JP5902148B2 (ja) | 2010-03-31 | 2016-04-13 | アベラ ファーマスーティカルズ インコーポレイテッド | 自閉症治療用ジメチルスルホキシド（ｄｍｓｏ）製剤 |
| BR112013033239A2 (pt) | 2011-06-22 | 2016-09-06 | Vyome Biosciences | pró-farmácos de conjugado baseado em atifungicos e antibacterianos |
| US9040082B2 (en) | 2011-06-24 | 2015-05-26 | K-Pax Pharmaceuticals, Inc. | Compositions and methods for treatment of chronic fatigue |
| US20120128683A1 (en) | 2011-11-22 | 2012-05-24 | Shantha Totada R | Autism treatment |
-
2013
- 2013-12-19 JP JP2015523309A patent/JP5973073B2/ja active Active
- 2013-12-19 PT PT138181821T patent/PT2838510T/pt unknown
- 2013-12-19 MX MX2016005998A patent/MX365663B/es active IP Right Grant
- 2013-12-19 DK DK13818182.1T patent/DK2838510T3/en active
- 2013-12-19 PL PL13818182T patent/PL2838510T3/pl unknown
- 2013-12-19 HU HUE13818182A patent/HUE032205T2/en unknown
- 2013-12-19 US US14/134,183 patent/US9326935B2/en active Active
- 2013-12-19 EP EP13818182.1A patent/EP2838510B1/en not_active Revoked
- 2013-12-19 WO PCT/US2013/076435 patent/WO2014204513A1/en not_active Ceased
- 2013-12-19 CN CN201380080783.2A patent/CN105705135A/zh active Pending
- 2013-12-19 SI SI201330306A patent/SI2838510T1/sl unknown
- 2013-12-19 ES ES13818182.1T patent/ES2605495T3/es active Active
-
2014
- 2014-01-10 TW TW103101018A patent/TWI583402B/zh active
-
2016
- 2016-04-04 IL IL244878A patent/IL244878A/en active IP Right Grant
- 2016-10-13 CY CY20161101032T patent/CY1118100T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5973073B2 (ja) | 2016-08-23 |
| JP2015522624A (ja) | 2015-08-06 |
| TW201431567A (zh) | 2014-08-16 |
| MX2016005998A (es) | 2016-07-18 |
| WO2014204513A1 (en) | 2014-12-24 |
| US20150133562A1 (en) | 2015-05-14 |
| CY1118100T1 (el) | 2017-06-28 |
| US9326935B2 (en) | 2016-05-03 |
| TWI583402B (zh) | 2017-05-21 |
| CN105705135A (zh) | 2016-06-22 |
| DK2838510T3 (en) | 2016-12-19 |
| EP2838510A1 (en) | 2015-02-25 |
| IL244878A0 (en) | 2016-05-31 |
| IL244878A (en) | 2017-04-30 |
| EP2838510B1 (en) | 2016-09-21 |
| MX365663B (es) | 2019-06-10 |
| SI2838510T1 (sl) | 2016-11-30 |
| PT2838510T (pt) | 2016-11-23 |
| HUE032205T2 (en) | 2017-09-28 |
| PL2838510T3 (pl) | 2017-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2605495T3 (es) | Solución de atomoxetina | |
| ES2907324T3 (es) | Composición farmacéutica líquida | |
| EA201270069A1 (ru) | Быстрорастворимая оральная пленочная лекарственная форма, содержащая стевиозиды в качестве агента, маскирующего неприятный вкус | |
| ES2617252T3 (es) | Solución oral que comprende clorhidrato de atomoxetina | |
| RU2008127860A (ru) | Фармацевтический состав для содержащих серу лекарств в жидких дозированных формах | |
| JP2015522624A5 (https=) | ||
| HRP20160286T1 (hr) | Tekuća farmaceutska kompozicija koja sadrži nitizinon | |
| AR109093A1 (es) | Solución oral que comprende clorhidrato de atomoxetina y sus métodos | |
| ES2598490T3 (es) | Disolución farmacéutica bebible de telmisartán | |
| JP2009256216A (ja) | 溶液状態で安定なアムロジピンベシル酸塩内服用液剤 | |
| ES2401402T3 (es) | Comprimidos efervescentes y gránulos efervescentes que contienen tartrato de carnitina | |
| ES2791721T3 (es) | Composición farmacéutica, dietética o alimenticia líquida o semilíquida sin amargor que contiene una sal de arginina | |
| ES2519592T3 (es) | Composiciones sólidas farmacéuticas que contienen sales de ibuprofeno | |
| HRP20220691T1 (hr) | Poboljšanja u i u vezi s pripravcima | |
| ES2637521T3 (es) | Formulaciones de aripiprazol | |
| JP2012036167A (ja) | 内服液剤 | |
| RU2010136277A (ru) | Галеновая форма для трансмукозально-буккального введения триптанов | |
| CN101330920A (zh) | 内服用液体制剂 | |
| WO2015126265A1 (en) | Oral liquid vitamin supplements containing zinc and stabilized vitamin c with reduced astringency | |
| ES2671543T3 (es) | Composición farmacéutica de citrato de sildenafilo en forma de suspensión para uso oral | |
| JP5891694B2 (ja) | 内用液剤組成物 | |
| JP5830855B2 (ja) | 液剤組成物 | |
| RU2778647C2 (ru) | Фармацевтическая композиция в виде водного раствора, предпочтительно сиропа, содержащая инозина пранобекс и глюконат цинка, и способ ее получения | |
| ES2356828T3 (es) | Preparados para gotas que comprenden dimentindeno. | |
| GR1009069B (el) | Ποσιμα διαλυματα υψηλης συγκεντρωσης που περιεχουν υδροχλωρικη ρανιτιδινη |